Global Cephalosporin Drugs Market - Regional Insights
On the basis of region, the global cephalosporin drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global cephalosporin drugs market during the forecast period, owing to increasing number of product launches. For instance, in August 2017, Dr. Reddy’s Laboratories Ltd. launched Cefixime for Oral Suspension, a therapeutic equivalent generic version of Suprax (cefixime) for Oral Suspension, in the U.S. market. The Suprax brand and generic had US sales of approximately US$ 50.5 million for the 12 months ended in June 2017..
Asia Pacific is expected to foresee a rapid growth in the cephalosporin drugs market. The market in Asia Pacific is expected to gain momentum during the forecast period, owing to increasing strategic partnership for distribution of cephalosporin drugs. For instance, in September 2017, Basilea Pharmaceutica Ltd. announced that its subsidiary, Basilea Pharmaceutica International Ltd. (Basilea), entered into a license agreement with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd. for Basilea's antibiotic Zevtera (ceftobiprole) in China.
Cephalosporin Drugs Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients